PARIS, Sept 12 - In July, Geneva Proteomics of Switzerland made a bold announcement, saying it planned to become the international leader in industrialized proteomics.

Armed with some of the leading brains in proteomics and $40 million in venture capital, the possibility that GeneProt would be able to conquer the market might have seemed feasible.

But on closer inspection many questions arise about how the company will achieve such an audacious goal.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.